Scancell shares healthy following patent approval award in Japan
Shares in cancer vaccine developer Scancell rose on Wednesday after the company announced its ImmunoBody Patent had been approved in Japan.
Shares in cancer vaccine developer Scancell rose on Wednesday after the company announced its ImmunoBody Patent had been approved in Japan.
The same patent has already been approved in the US, Europe and Australia.
Dr Richard Goodfellow, Joint Chief Executive Officer of Scancell, commented: "This is a further important step in the development and commercialisation of the ImmunoBody platform and provides further evidence to support the novelty of Scancell's ImmunoBody technology in another key pharmaceutical market.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"Scancell will continue building its growing portfolio of intellectual property in parralel with driving the clinical trial programme on SCIBI forward during 2013."
SCIBI is Scancell's first cancer vaccine which is currently being developed for the treatment of melanoma.
Scancell's share price was up 6.37% to 41.75p at 11:01 on Wednesday.
MF
-
Boost for over 100,000 families on Child Benefit as new HMRC payment system rolled outThousands of households will no longer have to pay the dreaded High Income Child Benefit Charge through self-assessment
-
Are you being haunted by the ghost of Christmas past? How festive cutbacks could boost your long-term wealthThe average family spends around £1,000 over the Christmas season. Here’s how much you could have gained if you had invested some of the money instead.
